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Abstract
Poor HIV care retention impedes optimal treatment outcomes in persons living with HIV. Women 
trying to become pregnant may be motivated by periconception horizontal and vertical 
transmission concerns and thus more likely to attend HIV care visits than women not trying to 
conceive. We estimated the effect of fertility intentions on HIV care attendance over 12 months 
among non-pregnant, HIV-positive women aged 18–35 years who were on or initiating 
antiretroviral therapy in Johannesburg, South Africa. The percentage of women attending an HIV 
care visit decreased from 93.4% in the first quarter to 82.8% in the fourth quarter. Fertility 
intentions were not strongly associated with care attendance in this cohort of reproductive-aged 
women; however, attendance declined over time irrespective of childbearing plans. These findings 
suggest a need for reinforced efforts to support care engagement and risk reduction, including 
safer conception practices for women wishing to conceive.
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Introduction
Sustained engagement in HIV care is required for optimal clinical and prevention outcomes. 
Although advances in global antiretroviral therapy (ART) programs have expanded 
treatment availability for persons living with HIV (1), poor attendance at clinical care visits, 
high loss to follow-up, and inadequate ART use continue to impede efforts to optimize 
treatment and prevention worldwide (2, 3).
One factor that that may influence engagement in care is decision-making around 
childbearing. Women who are trying to conceive have different clinical needs than women 
not trying to become pregnant (4), potentially precipitating differences in the frequency with 
which women attend HIV clinical care visits. Women who are conscious of their pregnancy 
plans may be motivated to adopt healthier behaviors in the preconception period (5), 
including improved ART adherence to maintain their own physical health. Concerns about 
horizontal transmission (6, 7) or mother-to-child transmission (8) may also motivate women 
who are planning to conceive to have a more consistent relationship with HIV care, 
particularly among those who discussed their fertility intentions with a provider or those 
who were counseled on reducing transmission risk during an earlier pregnancy.
In South Africa and other sub-Saharan African settings, research around ART adherence and 
periconception HIV care retention is largely framed around prevention of mother-to-child 
transmission (PMTCT) (9–11), and relatively few studies have explicitly evaluated HIV 
treatment outcomes in women outside of the pregnancy and postpartum periods (10, 12–14). 
In particular, few studies have explicitly assessed the relationship between fertility intentions 
and retention in HIV care. Here, we estimated the effect of fertility intentions on attendance 
at HIV clinical care visits among HIV-positive women on ART in Johannesburg, South 
Africa.
Methods
Study Setting, Population and Procedures
We performed a secondary analysis of longitudinal data from a prospective cohort study 
conducted in Johannesburg between 2009 and 2011. This original study was designed to 
estimate the 12-month incidence of pregnancy in HIV-positive women on ART. Full 
descriptions of study procedures and eligibility criteria have been published elsewhere (15–
19). Briefly, non-pregnant, sexually active women between the ages of 18 and 35 years 
receiving ART care at one of four public community or primary health clinics were eligible 
for participation if they had not been pregnant in the last three months; were not 
breastfeeding; had not had a previous tubal ligation, hysterectomy, or bi-lateral 
oophorectomy; and had not been diagnosed as permanently infertile. Pregnancy was 
assessed using a urine-based pregnancy test (One Step hCG Urine Pregnancy Test, Atlas 
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Link Technology, Beijing) at enrollment. After providing written informed consent, eligible 
women completed an interviewer-administered questionnaire. Questionnaires assessed 
demographic characteristics, fertility history and intentions, contraceptive use, and sexual 
risk behaviors. ART regimen information, CD4 cell count and viral load data were 
abstracted through medical records, pharmacy, and laboratory records.
Study follow-up visits coincided with routine HIV care visits, every 1–3 months based on 
clinic protocol and ART supply. During follow-up visits, women were assessed for 
pregnancy (via urine-based pregnancy test) and updated HIV-associated clinical 
characteristics were recorded (i.e., CD4 count and HIV viral load). Current contraceptive use 
and fertility intentions were assessed at each visit using a short questionnaire.
Fertility intentions were measured at enrollment using three questions that asked about 
current and future childbearing plans. Women were first asked if they were trying to 
conceive at time of interview (yes/no). Those who said no were then asked if they were 
planning to conceive in the next 12 months (yes/no/uncertain). Those who said no or were 
uncertain were then asked if they were planning to conceive someday in the future (yes/no/
uncertain).
During follow-up, women were only asked if they were trying to conceive at the time of 
each HIV clinical care visit (yes/no).
Exposure and Outcome Definitions
We created three dichotomous exposure variables for fertility intentions: two time-fixed 
variables based on assessments at enrollment and one time-varying variable based on 
assessments across follow-up. We first created a time-of-enrollment variable reflecting 
short-term plans for childbearing. Those reporting at enrollment that they were currently 
trying to conceive, as well as those who answered “yes” or “uncertain” to the question about 
plans to conceive in the next 12 months, were classified as having short-term plans for 
childbearing. Those who answered “no” at enrollment to questions about current or 12-
month conception plans were classified as not having short-term plans for childbearing. We 
constructed a second dichotomous time-of-enrollment variable to reflect any plans for 
childbearing, classifying those answering “yes” or “uncertain” to any of the three questions 
about conception intentions (at time of interview, in the next 12 months, or someday in the 
future) as having plans for childbearing; those answering “no” to all three fertility intentions 
questions were classified as not having plans for childbearing. Third, we created a time-
varying dichotomous variable reflecting current fertility intentions, basing classifications on 
the single yes/no question assessing current conception attempts at the time of interview in 
each quarter. In sensitivity analyses, women with uncertain fertility intentions (time-fixed 
variables only) were re-classified as having no plans to conceive.
To estimate the effect of each categorization of fertility intentions on attendance at HIV 
clinical care visits, we constructed an analytic cohort in which each woman was followed 
from study enrollment through the completion of 12 months of follow-up or until date of 
censoring if she became pregnant or died. We partitioned the 12-month follow-up period 
into three-month intervals (quarters). Attendance at HIV clinical care visits was assessed 
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dichotomously in each quarter: a woman was classified as having attended a visit in a given 
interval if she attended one or more routine HIV clinical care visits in that interval.
Statistical Analysis
Demographic and clinical characteristics of women at enrollment were described using 
proportions for categorical variables and medians for continuous variables. Chi-square tests 
were used to compare the differences in proportions between groups for categorical 
variables, and Wilcoxon signed-rank sum tests were used for continuous data ( = 0.05).
We used an extension of the modified Poisson regression model (20, 21) to estimate risk 
ratios for the association between care attendance and each exposure variable. To estimate 
risk differences, we fit Poisson models with an identity link and a robust variance estimator 
under a generalized estimating equations (GEE) framework (22). For each comparison, an 
exchangeable correlation structure was specified to account for within-subject correlation 
between outcomes (multiple intervals of potential care attendance per woman) (23). To 
ensure temporality in our analysis of time-varying fertility intentions – that is, to ensure that 
the fertility intentions measure preceded a given care attendance measure – we included a 
time lag. More specifically, we assessed attendance quarterly among women who reported 
they were either trying or not trying to conceive at their visit in the previous quarter.
To determine whether the relationship between fertility intentions (assessed at enrollment) 
and care attendance varied by treatment experience, we considered potential effect measure 
modification (EMM) by ART duration and CD4 count (using most recently collected CD4 
[median time since CD4 testing 3.2 months (IQR 2, 5)]) assessed at enrollment. To assess 
EMM by ART duration, we compared women who had initiated or reinitiated ART within 
three months of study enrollment (recent initiators) with those who had been on ART for 
more than three months (ART experienced). CD4 count was categorized as <200 or ≥200 
cells/ml. To formally test for EMM, we included an interaction term between the time-fixed 
dichotomized exposure measures of fertility intentions and each of the proposed modifiers. 
We considered both the magnitude and precision of stratum-specific estimates when making 
a final determination of EMM.
All analyses were conducted using SAS statistical software (SAS, version 9.4, Cary, NC).
Weights
To address potential selection bias in this analysis we constructed two sets of weights. First, 
to account for the possibility of informative censoring (whereby censoring due to pregnancy 
or death was associated with the exposure/outcome) we calculated time-varying inverse 
probability of censoring weights. Pooled logistic regression models were used to estimate 
censoring weights for each exposure, and weights were stabilized and multiplied over time 
(24). Second, in our analysis of time-varying fertility intentions, we applied inverse 
probability of selection weights to account for missing exposure information due to a missed 
visit in the prior interval (25). The probability of having an observed exposure measure was 
modeled as a function of age, CD4 count and having prior children, and weights were 
stabilized by the marginal probability of having an exposure measure that was observed.
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To account for confounding, we used stabilized inverse probability of exposure weights 
(IPW) to calculate weighted risk ratios and risk differences (26). A minimally sufficient set 
of covariates for attendance and each categorization of fertility intentions was identified 
using a causal directed acyclic graph (27). Covariates in the minimally sufficient set were 
measured at enrollment and included age, marital status, ART duration, partner fertility 
intentions and having prior children. Our use of censoring weights and selection weights 
informed our decision to use IPW instead of other adjustment methods. For each exposure, 
IPW were stabilized by the marginal probability of having that exposure and weights were 
truncated at the 5th and 95th percentiles to further improve stability.
Results
We enrolled 850 women between August 2009 and January 2010 and followed them for up 
to 12 months. Over the 12-month follow-up period, 149 women (17.5%) became pregnant 
and contributed a median of 6.2 months (IQR 4, 9) of follow-up before they were censored. 
No deaths were reported during follow-up. Twenty-eight (3.8%) women did not return to 
care after their initial study visit. Women were a median of 30.4 years old at enrollment 
(IQR 27, 33) and fewer than half were married or co-habiting (44.5%) (Table 1). Most 
(89.4%) had previously been pregnant. Median time since HIV diagnosis was 24.0 months 
(IQR 12, 48), and median time since ART initiation was 13.2 months (IQR 5, 24).
Approximately half (46.6%) of women reported having short-term plans for childbearing 
(either trying to become pregnant at time of interview or sometime within the next 12 
months) at enrollment, including 12.4% who were trying to conceive at enrollment. 
Compared to women without plans to conceive in the short term, women with short-term 
childbearing plans were more likely to be married/co-habiting (50.3% vs. 39.4%), less likely 
to have been previously pregnant (82.6% vs. 95.3%), and less likely to be taking hormonal 
contraception (18.4% vs. 33.3%). The proportion of women who had achieved viral 
suppression (<50 copies/ml) was similar in both groups.
The overall probability of attending an HIV clinical care visit decreased from 93.4% in the 
first quarter to 82.8% in the fourth quarter. When we compared women with short-term 
plans for childbearing at enrollment to those without short-term plans, we detected no 
difference in attendance in unweighted and weighted models (Table 2). When we compared 
women with any plans for childbearing at enrollment to those reporting no such plans, care 
attendance was also similar between groups. Results did not change substantively in 
sensitivity analyses where women with uncertain fertility intentions were re-classified as 
having no plans to conceive (Online Appendix 1). In our assessment of time-varying fertility 
intentions, women who were trying to conceive at a particular visit were slightly more likely 
to attend an HIV clinical care visit in the following quarter than women who were not trying 
to conceive at that time (RR 1.03 (95% CI 1.00, 1.06); RD 0.03 (95% CI 0.00, 0.05)). 
However, attendance was >80.0% in the fourth quarter for both groups. There did not appear 
to be modification by ART duration or CD4 count (Online Appendix 2).
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Discussion
In this study of South African women on ART, we expected that women with immediate or 
short-term plans to conceive would exhibit greater care engagement than those with less 
proximal plans to become pregnant. Instead, we observed comparable engagement overall 
between these groups over the subsequent year. Care attendance in the subsequent quarter 
was marginally greater among women currently trying to conceive at a given visit compared 
to women who were not trying to conceive, but the estimated incremental difference in 
retention may not be programmatically meaningful in this population.
Maternal concerns around mother-to-child transmission are thought to motivate care 
attendance during pregnancy in some HIV-positive women (8, 13, 28–30), and we expected 
that women in our study would demonstrate similar health-seeking behaviors in the 
periconception period. Additionally, concerns about horizontal transmission to HIV-
uninfected partners during attempts to become pregnant could prompt better attendance at 
HIV clinical care visits among women trying to conceive (6, 7). However, we found little 
difference in care attendance among women with and without plans for childbearing (short-
term or any), an indication that fertility intentions may not markedly impact care attendance 
in this population.
Consistent with other short-term estimates of retention in South Africa (31), overall HIV 
care attendance in our study population remained >80% at the end of 12 months. As follow-
up began at study entry and not at a more clinically meaningful milestone (e.g., HIV 
diagnosis, linkage to care, ART initiation) (32), our population may have been biased 
towards women already enrolled and retained into long-term HIV care. As such, the 
relatively high proportion of attendance may have attenuated the magnitude of our effect 
estimates (33), thus affecting this study’s ability to identify differences in care attendance by 
different childbearing plans. In subgroup analysis among women who had recently initiated 
ART, however, estimates were largely similar to results in the full cohort, although precision 
was limited.
A strength of this study was our use of prospectively collected and time-updated measures of 
current fertility intentions that preceded pregnancy assessment, which may have reduced 
potential exposure misclassification (34, 35). Though dynamic, fertility intentions are often 
not assessed routinely within the context of HIV clinical care (36, 37), and so we also 
considered baseline (time-fixed) fertility intentions measures pertaining to less proximal 
time horizons that enabled us to assess a range of childbearing scenarios and their respective 
effects on HIV care attendance. Furthermore, although more multidimensional measures of 
fertility intentions may provide additional insights into women’s family planning needs (38, 
39), the measures of fertility intentions included in this study were highly predictive of 
pregnancy incidence among women with stated intentions to conceive in this study 
population (15, 16).
This analysis has some limitations. First, women in this study who missed one or more 
routine HIV care visits may have engaged in care elsewhere without our knowledge (40). 
However, attendance was relatively high among all participants, minimizing the likelihood 
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that any misclassification of missed visits would have biased the overall interpretation of our 
results (33). Second, our assessment of attendance using quarterly visits may have 
disregarded circumstances in which women were advised to return to care more than three 
months after a given visit. Because date of next clinic visit was not routinely collected 
during the study period, a “days late” or “missed appointments” definition of care 
disengagement was not possible (41). Third, questions regarding exposure to safer 
conception services were administered only at the end of follow-up (17), and thus we were 
unable to ascertain whether or not safer conception knowledge modified the relationship 
between fertility intentions and care attendance in this analysis. Fourth, data included in this 
study were collected prior to South African national service delivery guidelines around 
earlier thresholds for treatment initiation, and thus the generalizability of our results to the 
modern era of universal treatment is uncertain. Finally, we cannot discount the possibility of 
unmeasured confounding, although all confounders identified by our directed acyclic graph 
were included in final models.
While retention remained relatively high in this population, by just 12 months attendance 
was predicted to have decreased to approximately 80% irrespective of childbearing plans. To 
the extent that routine HIV care visits present opportunities to offer contraceptive counseling 
and pregnancy testing, missed visits may prevent women in this population from fully 
meeting their family planning needs. We have previously reported both a high probability of 
unmet need for contraception (19) and a high incidence of unplanned pregnancy in this 
cohort (16). Though an assessment of unmet need for contraception and its relationship with 
care attendance was beyond the scope of this analysis, only 26% of women reported using a 
method of hormonal contraception to prevent pregnancy at enrollment. Contraceptive use 
among those without more immediate plans for pregnancy was notably only 33%.
Our findings reaffirm the need for expanded efforts to help women to remain engaged in 
HIV care, including during the periconception period. Routine screening of fertility 
intentions, accompanied by rapid referrals for safer conception, may offer the potential to 
improve periconception care engagement and HIV transmission prevention in South Africa. 
Safer conception services, which support the reproductive goals of HIV-positive women and 
their partners, can reduce the risks of HIV transmission through pregnancy and pregnancy 
attempts, identify and treat sexually transmitted infections, and potentially engage sexual 
partners to optimize care delivery (42). For women who are already attending routine HIV 
care visits in the periconception period, safer conception counseling can promote ART 
adherence and encourage limiting pregnancy attempts until viral suppression can be 
achieved and maintained. Viral suppression prevalence was just 71% among women with 
short-term plans to conceive in this study, highlighting the need for reinforced efforts to 
support care engagement and risk reduction strategies during periconception. While safer 
conception has been found to be both acceptable and feasible in South Africa (43), services 
remain largely unavailable outside of research settings (4). Our study contributes to a 
growing body of evidence that supports routine implementation of safer conception services 
during periconception to increase care engagement and optimize HIV prevention in this 
population.
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In summary, our findings suggest that women with plans for pregnancy have comparable 
engagement in care to other women. However, we report a non-trivial decline in attendance 
over a 12-month period among both women with and without plans for childbearing, as well 
as a suboptimal viral suppression prevalence among women with plans to conceive. Efforts 
to ensure sustained care engagement and treatment adherence after ART initiation, 
particularly during periconception, remain critical.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Table 1.
Characteristics at enrollment of 850 women with HIV taking ART in Johannesburg, 2009–2011
Overall N=850 (100.0%) Short-term childbearing plans 
N=396 (46.6%)
Long-term or no childbearing 
plans N=454 (53.4%)
Median IQR Median IQR Median IQR p-valuea
Age (years) 30.4 27–33 30.0 28–33 31.0 28–34 0.55
No. living children 1.0 1–2 1.0 0–1 2.0 1–2 <0.01
Months since HIV 
diagnosis
24.0 12–48 24.0 12–48 24.5 12–48 0.11
CD4 count, cells/ml 312.0 178–462 270.5 169–425 345.5 196–492 <0.01
Months on ART 13.2 5–24 10.8 3–22 14.0 7–27 <0.01
n % n % n %
Married/cohabitating 378 44.5 199 50.3 179 39.4 <0.01
Ever pregnant 760 89.4 327 82.6 433 95.3 <0.01
Trying to conceive, 
currently
105 12.4 105 26.5 0 0 .
Taking hormonal 
contraception
224 26.4 73 18.4 151 33.3 <0.01
Pregnant at HIV diagnosis 271 31.9 84 21.2 187 41.2 <0.01
Viral load <50 copies/mlb 618 74.1 277 71.2 341 76.6 0.07
Abbreviations; IQR: Interquartile Range, No: Number, ART: Antiretroviral therapy
aChi-square tests were used to compare the differences in proportions between groups for categorical variables, and Wilcoxon signed-rank sum 
tests were used for continuous data ( = 0.05).
b
n=834
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Table 2.
Unweighted and Weighted Risk Ratios (RRs), Risk Differences (RDs) and 95% CIs for the effect of fertility 
intentions on quarterly attendance at HIV clinical care visits among 850 women with HIV taking ART in 
Johannesburg, 2009–2011
Unweighted Weighted
RR (95% CI) RD (95% CI) RR (95% CI) RD (95% CI)
Short-term childbearing plans a
 yes 0.98 (0.96, 1.00) −0.02 (−0.05, 0.01) 0.99 (0.96, 1.02) −0.01 (−0.05, 0.02)
 no REF REF REF REF
Any childbearing plans b
 yes 1.00 (0.97, 1.03) 0.00 (−0.04, 0.03) 1.01 (0.96, 1.06) 0.01 (−0.05, 0.06)
 no REF REF REF REF
Currently trying to conceive (time-varying) c
 yes 1.01 (0.98, 1.04) 0.01 (−0.02, 0.04) 1.03 (1.00, 1.06) 0.03 (0.00, 0.05)
 no REF REF REF REF
Abbreviations. RR: risk ratio; RD: risk difference; CI: confidence interval; ART: Antiretroviral therapy
aWeighted effect estimates account for censoring (mean=1.01; range 0.37–2.26) and confounding by age (≤30, >30 years), marital status (married 
or co-habitating/not married or co-habitating), time on ART (initiated ART ≤3 vs. >3 months before enrollment), partner fertility intentions (no 
partner, partner does not desire a/another child, partner unsure, partner desires a/another child) and any prior living children (yes/no) (mean=0.99; 
range 0.49–4.18)
bWeighted effect estimates account for censoring (mean=1.00; range 0.40–1.73) and confounding by age (≤30, >30 years), marital status (married 
or co-habitating/not married or co-habitating), time on ART (initiated ART ≤3 vs. >3 months before enrollment), partner fertility intentions (no 
partner, partner does not desire a/another child, partner unsure, partner desires a/another child) and any prior living children (yes/no) (mean=0.97; 
range 0.34–3.19)
cWeighted effect estimates account for censoring (mean=1.00; range 0.42–1.86), selection (mean=1.04; range 0.54–1.65), and confounding by age 
(≤30, >30 years), marital status (married or co-habitating/not married or co-habitating), time on ART (initiated ART ≤3 vs. >3 months before 
enrollment), partner fertility intentions (no partner, partner does not desire a/another child, partner unsure, partner desires a/another child) and any 
prior living children (yes/no) (mean=0.97; range 0.26–1.93)
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